Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Psoriatic arthritis (PsA) is a complex rheumatic disease with severity that ranges from mild to severe. The mild form of PsA can be referred to as oligoarticular (OLIGO), whereas more severe cases are considered polyarticular (POLY) form. Furthermore, peripheral joint and
Methods: Biologic Treatment Registry Across Canada (BioTRAC) is an ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis, ankylosing spondylitis, or PsA with Infliximab, GLM, or ustekinumab for PsA. PsA patients treated with GLM who were enrolled since 2010 were eligible for the analysis. OLIGO involvement was defined as (≤2 SJC) and POLY (>2 SJC), while axial involvement included spinal symptoms or spondylitis with peripheral arthritis. Minimal disease activity (MDA) was defined as the fulfillment of ≥5 of the following criteria: TJC28≤1, SJC28≤1, PASI≤1 or BSA≤3, Pain (VAS)≤15mm, PtGA (VAS)≤20mm, HAQ ≤0.5, tender entheseal points ≤1.
Results: A total of 201 PsA patients were included in this analysis; 30.8% had oligoarthritis, 68.0% had polyarthritis, while 26.0% had axial involvement at baseline. Baseline parameters are described by axial involvement and articular involvement (Table 1). Increased baseline disease activity was observed among patients with axial involvement for MDGA, PtGA, pain, and presence of enthesitis (p<0.05). Patients with polyarthritis were older, less likely to have been previously treated with a biologic, and had significantly (p<0.05) higher SJC28, TJC28, morning stiffness, MDGA, PtGA, pain, DAS28, HAQ, and enthesitis at GLM initiation. At 6 months, statistically significant between group differences were observed for MDA achievement. There were significantly lower proportions of patients achieving MDA among patients with axial involvement (26.7% vs. 61.8%, p=0.020) and polyarthritis (35.9% vs. 80.0%, p<0.001). Multivariate logistic regression analysis showed that patients with oligoarticular involvement (OR=3.92; p=0.035), younger age (OR=0.96; p=0.051), and lower baseline HAQ (OR=0.32; p=0.007) were associated with higher odds of MDA achievement at 6 months of treatment while axial involvement did not have a significant impact.
Conclusion: The results of the current analysis highlight that differences exist in the baseline patient profile based on the presence or absence of axial involvement and POLY involvement among PsA patients treated with GLM. Furthermore, OLIGO disease was identified as a significant independent predictor of MDA achievement with almost a four-fold higher likelihood of achieving target relative to patients with polyarthritis.
To cite this abstract in AMA style:Khraishi MM, Rahman P, Tsoukas A, Kapur S, Baker MF, Jones N, Starr M, Rampakakis E, Psaradellis E, Maslova K, Nantel F, Lehman AJ, Tkaczyk C, Osborne B. Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/articular-and-axial-involvement-differences-in-psoriatic-arthritis-patients-treated-with-golimumab-in-canadian-real-world-practice/. Accessed November 25, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/articular-and-axial-involvement-differences-in-psoriatic-arthritis-patients-treated-with-golimumab-in-canadian-real-world-practice/